TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE AND ANEMIA OR IRON DEFICIENCY
Keywords:anemia, iron deficiency, chronic heart failure, treatment.
AbstractAnemia and iron deficiency is widespread among patients with chronic heart failure (CHF) and is associated in such patients with reduced ability to exercise, a deterioration in the quality of life and a worse prognosis, regardless of the presence of anem
Gonzalez-Costello, J. et al. (2020) ‘Use of intravenous iron in patients with iron deficiency and chronic heart failure: Real-world evidence’, European Journal of Internal Medicine, 80(March), pp. 91–98. doi: 10.1016/j.ejim.2020.04.031.
Anker, S. D. et al. (2009) ‘Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency’, New England Journal of Medicine, 361(25), pp. 2436–2448. doi: 10.1056/nejmoa0908355.
Ponikowski, P. et al. (2015) ‘Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency’, European Heart Journal, 36(11), pp. 657–668. doi: 10.1093/eurheartj/ehu385.
Jankowska, E. A. et al. (2015) ‘Effects of Intravenous Iron Therapy in Iron Deficient Patients With Systolic Heart Failure: Meta-Analysis of Randomized Control Trials’, Journal of the American College of Cardiology, 65(10), p. A854. doi: 10.1016/s0735-1097(15)60854-3.
Walther, C. P., Triozzi, J. L. and Deswal, A. (2020) ‘Iron deficiency and iron therapy in heart failure and chronic kidney disease’, Current opinion in nephrology and hypertension, 29(5), pp. 508–514. doi: 10.1097/MNH.0000000000000630.
Yancy, C. W. et al. (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer, Circulation. doi: 10.1161/CIR.0000000000000509.
Ponikowski, P. et al. (2016) ‘2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure’, European Heart Journal, 37(27), pp. 2129-2200m. doi: 10.1093/eurheartj/ehw128.
Ezekowitz, J. A. et al. (2017) ‘2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure’, Canadian Journal of Cardiology, 33(11), pp. 1342–1433. doi: 10.1016/j.cjca.2017.08.022.
Ponikowski, P. et al. (2020) ‘Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial’, The Lancet, 396(10266), pp. 1895–1904. doi: 10.1016/S0140-6736(20)32339-4.
Vifor Pharma Ltd. Ferinject (ferric carboxymaltose). Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/24167/SPC/Ferinject. (3 August 2018)
Magrì, D. et al. (2019) ‘Anemia and Iron Deficiency in Heart Failure: Clinical and Prognostic Role’, Heart Failure Clinics, 15(3), pp. 359–369. doi: 10.1016/j.hfc.2019.02.005.
McDonagh, T. et al. (2018) ‘Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice’, European Journal of Heart Failure, 20(12), pp. 1664–1672. doi: 10.1002/ejhf.1305.
Lewis, G.D. et al. (2017) ' Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial', The Journal of the American medical assosiation, 317(19), p.1958-1966, doi: 10.1001/jama.2017.5427
How to Cite
Copyright (c) 2022 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.